Copyright
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Sep 27, 2024; 16(9): 1199-1205
Published online Sep 27, 2024. doi: 10.4254/wjh.v16.i9.1199
Published online Sep 27, 2024. doi: 10.4254/wjh.v16.i9.1199
Functional cure of chronic hepatitis B-hope or hype?
Gautam Ray, Gastroenterology Unit, Department of Medicine, B.R.Singh Hospital, Kolkata 700014, West Bengal, India
Author contributions: Ray G designed the overall concept and outline of the manuscript along with the writing, literature review, discussion and illustration.
Conflict-of-interest statement: No conflict of interest to declare.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Gautam Ray, DNB, MD, Additional Chief Health Director, Gastro
Received: May 14, 2024
Revised: August 25, 2024
Accepted: September 2, 2024
Published online: September 27, 2024
Processing time: 131 Days and 20.8 Hours
Revised: August 25, 2024
Accepted: September 2, 2024
Published online: September 27, 2024
Processing time: 131 Days and 20.8 Hours
Core Tip
Core Tip: Due to underperformance of the World Health Organization policy of 2016 to eliminate hepatitis B by 2030, the disease burden remains substantial and there is an unmet need for newer curative therapies due to the inability of the presently approved therapies to completely eradicate the virus. Many novel molecules are in Phase I/II trials but only a few have shown preliminary encouraging results only in combination with pegylated interferon and/or nucleos(t)ide analogues with the risk of adverse events. As drug development will be a lengthy process, the present emphasis should still be on improving preventive measures such as vaccination, increasing diagnosis and linkage to care.